Primary tabs

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A phase III double-blind extension placebo-controlled parallel group safety and efficacy trial of BI 10773 10 and 25mg once daily and sitagliptin 100mg once daily given for minimum 76 weeks incl 24 weeks of preceding trial as monotherapy or with...

To investigate the long-term safety and tolerability of BI 10773 10 and 25 mg once daily

FieldValue
Modified
2019-08-06
Release Date
2018-05-05
Identifier
66e0d377-e36c-4ce4-8dad-4b9c3b2c4195
License
Public Access Level
Public